Signature Medical is developing AcoustiCare, its flagship wearable product focused on heart failure evaluation and monitoring to improve patient outcomes while preventing hospital re-admissions.
It differs from other typical sensor-based wearables with its proprietary cloud-based audio technology and artificial intelligence enabling remote monitoring and evaluation of heart failure and other indications.
Proceeds from this financing will be used to accelerate the development and commercialization of the AcoustiCare system.
Signature Medical offers innovative solutions focused on value-based healthcare initially focused on heart failure. It is dedicated to improving outcomes while reducing costs in high-value, large underserved markets using proprietary cloud-based and wearable technology.
Riot is an early-stage venture fund that invests in emerging technologies such as artificial intelligence, internet of things, autonomous vehicles, robotics, and augmented and virtual reality. Riot is headquartered in Boston with offices in Los Angeles.
Bose Corp. invests in long-term research with one fundamental goal: to develop new technologies with real customer benefits. Bose innovations have spanned decades and industries, creating and transforming categories in audio and beyond.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA